There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures.
The first-of-its-kind ADC Toxicity Summit allowed companies developing ADCs to overcome toxicological related challenges, by hearing case-study-led presentations on approved ADCs, including ImmunoGen’s Mirvetuximab Soravtansine, as well as important scientific and strategic discussions. Designed to provide you with the toolkit to design and deliver more tolerable ADCs to patients without lowering efficacy this was the exclusive opportunity to join peers with expertise in toxicology, safety, and pathology.
The ADC Toxicity Summit is your perfect platform to overcome where others have failed and accelerate more ADCs through preclinical development into the clinic and to market.
Take a look at what the 2023 meeting explored:
How to select the most optimal in vivo and in vitro models for your nonclinical safety study design to improve your translatability of toxicities into humans with Seagen, AbbVie, and Macrogenics
Utilizing your preclinical toxicity data to better inform your clinical trial design and improve your chances of clinical success with Bionavigen and Elucida Oncology
Learning how to manage and mitigate your toxicities in the clinic to expand your therapeutic windows with case study led examples from Immunogen and Dana-Farber Cancer Institute
Optimize your dosage by gaining an understanding of pathology and PK/PD studies to inform your dose translatability and escalation with Eisai
Honing in on your ADC design to uncover ideal linker stability and antibody-payload ratio to minimize off-target toxicities in your drug development with Bristol Myers Squibb, Iksuda and Zymeworks
What Your Peers Had to Say:
“It’s exciting to be viewing the current landscape of learnings from non-clinical to clinical safety assessments for ADCs and how that may inform on R&D efforts to enable future transformational therapies in the clinic” - Ronnie Yeagen
“An early anticipation and understanding of the type and source of toxicities that may be encountered with an ADC is critical to successful clinical development. I’m excited to participate in this conference to learn and share information that will help us all develop safer and more effective ADCs" - Greg Adams